NPC(SH:600713) Xin Lang Zheng Quan·2025-10-30 15:15Core Viewpoint - Nanjing Pharmaceutical is a well-known enterprise in the domestic pharmaceutical distribution sector, with a comprehensive business model that includes wholesale, retail, and third-party logistics services [1] Group 1: Business Performance - In Q3 2025, Nanjing Pharmaceutical achieved a revenue of 41.135 billion, ranking 5th among 24 companies in the industry, with the industry leader, Shanghai Pharmaceutical, at 215.072 billion [2] - The main business composition includes wholesale at 26.506 billion, accounting for 94.87%, and retail at 1.245 billion, accounting for 4.46% [2] - The net profit for Q3 2025 was 530 million, ranking 9th in the industry, with the top performer, Shanghai Pharmaceutical, at 5.986 billion [2] Group 2: Financial Ratios - As of Q3 2025, Nanjing Pharmaceutical's debt-to-asset ratio was 76.62%, slightly down from 76.75% year-on-year, which is higher than the industry average of 59.74% [3] - The gross profit margin for Q3 2025 was 5.95%, down from 6.16% year-on-year, and below the industry average of 13.11% [3] Group 3: Executive Compensation - The chairman, Zhou Jianjun, received a salary of 1.8182 million in 2024, a decrease of 367,700 from 2023 [4] - The president, Zhang Liang, had a salary of 2.2384 million in 2024, an increase of 134,900 from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.73% to 51,600 [5] - The average number of circulating A-shares held per shareholder increased by 1.77% to 24,900 [5]